Proposed herein is the development of new chemistry for the de novo synthesisof carbohydrates and the use of this new methodology for the synthesis of new bioactivemolecules. These new bioactive structures may have activities against a range ofdiseases. This proposal is focus on anticancer and antibacterial compounds. Theapproach toward cancer is to use this new methodology to preform novel SAR studieson the carbohydrate portion of known natural products with anticancer activity. Thisapproach will be conducted on the carbohydrate portions of digitoxin, SL0101 andLandomycin A. With regard to antibacterial agents this proposal is focused onaddressing the problem of bacterial resistance. The major objectives of this proposal are to develop a concise methodologytoward unnatural sugars, to develop a method for the assembly of unnatural sugars intounnatural oligosaccharides and to incorporate these unnatural sugars into carbohydratebased antibiotics, etc. Having unnatural sugar analogues of these antibiotics/antitumoragents would greatly aid in revealing which functional groups are important to thesemolecular interactions and in turn help prepared new more potent drugs.

Public Health Relevance

This proposal intends to apply our palladium-catalyzed glycosylation for the de novo syntheses of several carbohydrate containing natural products and related compounds with important biological activities. These activities range from antibacterial to potential new cancer therapies. The long range expected outcome from this research effort is to develop and demonstrate a new methodology that will enable a medicinal chemist to mimic nature's use of rare and unnatural sugars in the Structure Activity Relationship (SAR) study of bioactive molecules. We anticipate that our Sugar Replacement Strategy, which installs simple sugars (i.e., under functionalized) into complex structural motifs, will drastically enable carbohydrate based drug discovery. This belief is based on the premise that there are many carbohydrate structures, which remain undiscovered because of synthetic limitations. Thus, allowing the discovery of new drugs (e.g., new antibiotics with activity towards multi-drug-resistant (MDR) bacteria, new anticancer agents, etc.). E. Human Subjects Not Applicable F. Vertebrate Animals Not Applicable

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
7R01GM088839-03
Application #
8206406
Study Section
Synthetic and Biological Chemistry A Study Section (SBCA)
Program Officer
Hagan, Ann A
Project Start
2009-08-15
Project End
2012-07-31
Budget Start
2010-09-01
Budget End
2012-07-31
Support Year
3
Fiscal Year
2010
Total Cost
$307,546
Indirect Cost
Name
Northeastern University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Ludwik, Katarzyna A; Campbell, J Preston; Li, Mingzong et al. (2016) Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Mol Cancer Ther 15:2598-2608
Bajaj, Sumit O; Sharif, Ehesan U; Akhmedov, Novruz G et al. (2014) De novo asymmetric synthesis of the mezzettiaside family of natural products via the iterative use of a dual B-/Pd-catalyzed glycosylation. Chem Sci 5:2230-2234
Sharif, Ehesan U; Wang, Hua-Yu Leo; Akhmedov, Novruz G et al. (2014) Merremoside D: de novo synthesis of the purported structure, NMR analysis, and comparison of spectral data. Org Lett 16:492-5
Mrozowski, Roman M; Sandusky, Zachary M; Vemula, Rajender et al. (2014) De novo synthesis and biological evaluation of C6?-substituted C4?-amide analogues of SL0101. Org Lett 16:5996-9
Pongrakhananon, Varisa; Stueckle, Todd A; Wang, Hua-Yu Leo et al. (2014) Monosaccharide digitoxin derivative sensitize human non-small cell lung cancer cells to anoikis through Mcl-1 proteasomal degradation. Biochem Pharmacol 88:23-35
Elbaz, Hosam A; Stueckle, Todd A; Wang, Hua-Yu Leo et al. (2012) Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells. Toxicol Appl Pharmacol 258:51-60
Mrozowski, Roman M; Vemula, Rajender; Wu, Bulan et al. (2012) Improving the affinity of SL0101 for RSK using structure-based design. ACS Med Chem Lett 4:175-179
Sharif, Ehesan U; O'Doherty, George A (2012) Biosynthesis and Total Synthesis Studies on The Jadomycin Family of Natural Products. European J Org Chem 2012:
Wang, Hua-Yu Leo; Xin, Wenjun; Zhou, Maoquan et al. (2011) Stereochemical survey of digitoxin monosaccharides: new anticancer analogues with enhanced apoptotic activity and growth inhibitory effect on human non-small cell lung cancer cell. ACS Med Chem Lett 2:73-78
Yu, Xiaomei; Li, Miaosheng; O'Doherty, George A (2011) DE NOVO ASYMMETRIC APPROACH TO THE DISACCHARIDE PORTION OF SCH-47554. Heterocycles 82:1577-1584

Showing the most recent 10 out of 19 publications